Abstract:1073 Objectives: Prostate-specific membrane antigen (PSMA) is expressed on the surface of most prostate cancer cells. The diagnosis and treatment of prostate cancer with PSMA as a target has been widely used in nuclear medicine. However, radionuclide imaging still has the disadvantages of low resolution and difficult to detect micro-lymph node metastases, and it may not be able to obtain the best therapeutic effect with single radionuclide therapy. In order to integrate the advantages of multiple imaging methods and improve the treatment efficiency, while the treatment process is monitored by PET/MR bimodal contrast imaging. We constructed an multimodal theranostic nanoprobe (89Zr,131I,Mn)PSMA-PEG-UMNPs, which can be used for multimodal imaging and bimodal therapy of prostate cancer. Methods: Organic melanin nanoparticles are prepared from naturally produced biopolymers. A small molecule inhibitor of prostate specific membrane antigen PSMA-SH was modified by mercaptopropionic acid on the basis of the original inhibitor. Positron radionuclide 89Zr was labeling to nanoprobe by using the metal adsorption function of UMNPs, as same as the paramagnetic metal ion Mn2+. Then N-Bromo Succinimide (NBS) was used as oxidant to oxidize active dihydroxyindole/indolequinone ring of UMNPs for electrophilic substitution reaction labeling 131I for constructing the prostate cancer specific integrated probe (89Zr, 131I, Mn) PSMA-PEG-UMNPs. Prostate cancer cells LNCaP and PC-3 were selected for cell experiment and the construction of tumor-bearing mouse model. The specific targeting function of nanoprobe for PSMA was tested by cell uptake experiment and micro-PET/CT imaging. Then the probe was injected to mouse model through tail vein for Micro-PET, PAI and PET/MR imaging. At the same time, the safety of nanoprobe and its biodistribution in tumor-bearing mice were detected. The bimodal therapeutic function of (89Zr, 131I, Mn) PSMA-PEG-UMNPs was detected by in vitro and in vivo experiment, several groups of models were set up for control experiment, and PET/MR imaging was used to monitor the treatment process. Results: The hydrated particle size of (131I, 89Zr, Mn) PSMA-PEG-UMNPs is about 14.36±1.77 nm. The radiochemical purity of 89Zr and 131I radionuclides are more than 98%, and the specific activity is more than 3.7 GBq/mol and 5.5 GBq/mol, respectively. Mn-PSMA-PEG-UMNPs have obvious enhancement effect in vitro T1-weighted magnetic resonance imaging, and its relaxation rate is about 2 times higher than that of commonly used MR contrast agent Gd-DTPA. Micro-PET/CT imaging and biodistribution of LNCaP tumor-bearing mice showed that the tumor site had high uptake of (89Zr, 131I, Mn) PSMA-PEG-UMNPs, and the uptake increased gradually with time. The biodistribution in vivo showed that the uptake at the tumor site of LNCaP tumor-bearing mice (8.92 ±0.37% ID/g) was significantly higher than that of PC-3 tumor-bearing mice (2.25 ±0.41%ID/g) after injection with (89Zr, 131I, Mn) PSMA-PEG-UMNPs at 24 h. In vivo photoacoustic imaging showed that the photoacoustic signal of LNCaP tumor-bearing mice gradually increased with time. The in vivo PET/MR fusion imaging showed that the T1-weighted signal intensity of LNCaP tumor was significantly increased and could be perfectly fused with PET signal after 4 hours of tail vein injection. In the part of treatment, after receiving combined RT and PTT, tumors of mice treated with (89Zr, 131I, Mn) PSMA-PEG-UMNPs plus laser irradiation were significantly damaged and showed greatly inhibited growth. The PET/MR imaging clearly monitored the changes of the tumor during treatment and continued to monitor for more than a week. Conclusions: (89Zr, 131I, Mn) PSMA-PEG-UMNPs can be successfully used for the multi-modal diagnostic and treatment of prostate cancer. PET/MR multimodal fusion imaging can monitor the process of tumor treatment, and it is expected to guide and improve the effect of treatment.

Real Time Ultrasound Molecular Imaging of Prostate Cancer with PSMA-targeted Nanobubbles

Molecular imaging of orthotopic prostate cancer with nanobubble ultrasound contrast agents targeted to PSMA

Functionalized NIR-II Semiconducting Polymer Nanoparticles for Single-cell to Whole-Organ Imaging of PSMA-Positive Prostate Cancer.

Optimized Anti–Prostate‐Specific Membrane Antigen Single‐Chain Variable Fragment–Loaded Nanobubbles As a Novel Targeted Ultrasound Contrast Agent for the Diagnosis of Prostate Cancer

Ultrasound-mediated drug-free theranostics for treatment of prostate cancer

Pharmacokinetic modeling of PSMA-targeted nanobubbles for quantification of extravasation and binding in mice models of prostate cancer

Quantification of extravasation and binding of PSMA-targeted nanobubbles by modelling the second-wave phenomenon

Targeted Nanobubbles Carrying Indocyanine Green for Ultrasound, Photoacoustic and Fluorescence Imaging of Prostate Cancer

Magnetic Polymeric Nanobubbles with Optimized Core Size for MRI/ultrasound Bimodal Molecular Imaging of Prostate Cancer

Multifunctional nanobubbles carrying indocyanine green and paclitaxel for molecular imaging and the treatment of prostate cancer

In Vivo Molecular MRI Imaging of Prostate Cancer by Targeting PSMA with Polypeptide-Labeled Superparamagnetic Iron Oxide Nanoparticles

Neuropeptide Y Y1 Receptor-Mediated Biodegradable Photoluminescent Nanobubbles As Ultrasound Contrast Agents for Targeted Breast Cancer Imaging

Combined Legumain- and Integrin-Targeted Nanobubbles for Molecular Ultrasound Imaging of Breast Cancer.

A Preliminary Study of PSMA Fluorescent Probe for Targeted Fluorescence Imaging of Prostate Cancer

Visualizing Tumors in Real Time: A Highly Sensitive PSMA Probe for NIR-II Imaging and Intraoperative Tumor Resection

Preparation of Targeted Nano-Microbubble Contrast Agent and Its Application in the Diagnosis of Prostate Cancer

Application Analysis of 124I-PPMN for Enhanced Retention in Tumors of Prostate Cancer Xenograft Mice.

Nanotechnology and cancer: improving real-time monitoring and staging of bladder cancer with multimodal mesoporous silica nanoparticles

Nanobubbles As Ultrasound Contrast Agent for Facilitating Small Cell Lung Cancer Imaging

Construction and Preclinical Study of Multi-modal Theranostic Integrated Probe for Prostate Cancer